Rockefeller Capital Management
ZNTL icon

Rockefeller Capital Management’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Rockefeller Capital Management’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-288
Closed -$5K – 3939
2022
Q4 		$5K Buy
288
+254
+747% +$5.46K ﹤0.01% 3351
2022
Q3 		$0 Hold
34
– – ﹤0.01% 4446
2022
Q2 		$0 Buy
+34
New +$901 ﹤0.01% 4434

Other funds holding ZNTL

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Rockefeller Capital Management's ZNTL Position: Q1 2023 in Review

Rockefeller Capital Management sold out of Zentalis Pharmaceuticals (ZNTL) in Q1 2023, closing a stake of 288 shares — an estimated $5K sold.

Rockefeller Capital Management first reported a position in ZNTL in Q2 2022 and held it in 3 quarters. The position peaked at $5K in Q4 2022. 110 funds tracked by Wall St. Rank hold ZNTL as of Q1 2023.

  • Rockefeller Capital Management reported no remaining Zentalis Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • Rockefeller Capital Management sold 288 Zentalis Pharmaceuticals shares in Q1 2023, an estimated $5K.
  • Rockefeller Capital Management first reported a position in Zentalis Pharmaceuticals in Q2 2022 and held it in 3 quarters.
  • Rockefeller Capital Management's Zentalis Pharmaceuticals position peaked at $5K in Q4 2022.
  • 110 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q1 2023.

Based on Rockefeller Capital Management's 13F filing for Q1 2023, filed 16 May 2023.